Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MARIELA BLUM MURPHY and JAFFER A AJANI.
MARIELA BLUM MURPHY
Connection Strength
11.920
JAFFER A AJANI
  1. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. Am J Clin Oncol. 2018 04; 41(4):321-325.
    View in: PubMed
    Score: 0.627
  2. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.604
  3. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016; 10(3):383-92.
    View in: PubMed
    Score: 0.534
  4. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. J Am Coll Surg. 2015 Jul; 221(1):83-90.
    View in: PubMed
    Score: 0.511
  5. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015 Jun; 111(7):875-81.
    View in: PubMed
    Score: 0.511
  6. Chemoradiation for esophageal cancer. Thorac Surg Clin. 2013 Nov; 23(4):551-8.
    View in: PubMed
    Score: 0.462
  7. Management of localized gastric cancer. J Surg Oncol. 2013 Mar; 107(3):265-70.
    View in: PubMed
    Score: 0.437
  8. Chemoradiation: Gastro-oesophageal cancer--is CROSSing over so hard to do? Nat Rev Clin Oncol. 2012 Sep; 9(9):493-4.
    View in: PubMed
    Score: 0.423
  9. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol. 2012 Mar 06; 9(4):194-5.
    View in: PubMed
    Score: 0.412
  10. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. Onkologie. 2011; 34(10):499-500.
    View in: PubMed
    Score: 0.399
  11. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol. 2011 Jun; 7(6):715-26.
    View in: PubMed
    Score: 0.391
  12. Three biomarkers (HER2, PD-L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience. Int J Cancer. 2024 Dec 15; 155(12):2277-2286.
    View in: PubMed
    Score: 0.242
  13. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer Med. 2024 May; 13(9):e7235.
    View in: PubMed
    Score: 0.239
  14. SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel. Cancers (Basel). 2024 Mar 27; 16(7).
    View in: PubMed
    Score: 0.238
  15. Therapeutic Advances in the Treatment of Gastroesophageal Cancers. Biomolecules. 2023 05 06; 13(5).
    View in: PubMed
    Score: 0.223
  16. Surveillance for esophageal cancer: does it make sense? J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1590-2.
    View in: PubMed
    Score: 0.217
  17. Localized Gastroesophageal Adenocarcinoma in the Elderly: Is Age a Factor Associated with Suboptimal Treatment? Oncology. 2023; 101(3):153-158.
    View in: PubMed
    Score: 0.216
  18. Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Ann Surg. 2021 04 01; 273(4):751-757.
    View in: PubMed
    Score: 0.193
  19. Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. Cancers (Basel). 2021 Jan 23; 13(3).
    View in: PubMed
    Score: 0.191
  20. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut. 2021 11; 70(11):2055-2065.
    View in: PubMed
    Score: 0.189
  21. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. Ann Surg. 2020 08; 272(2):311-318.
    View in: PubMed
    Score: 0.184
  22. Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology. 2020; 98(5):289-294.
    View in: PubMed
    Score: 0.179
  23. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2020 Aug; 27(8):2806-2811.
    View in: PubMed
    Score: 0.178
  24. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020 01; 69(1):18-31.
    View in: PubMed
    Score: 0.170
  25. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology. 2019; 96(5):252-258.
    View in: PubMed
    Score: 0.168
  26. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018; 95(2):81-90.
    View in: PubMed
    Score: 0.159
  27. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol. 2018 02; 13(1):99-106.
    View in: PubMed
    Score: 0.155
  28. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017; 93(4):243-248.
    View in: PubMed
    Score: 0.149
  29. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. J Surg Oncol. 2015 Dec; 112(8):883-7.
    View in: PubMed
    Score: 0.132
  30. Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference? Oncology. 2015; 89(4):215-20.
    View in: PubMed
    Score: 0.130
  31. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6.
    View in: PubMed
    Score: 0.127
  32. Medical management of gastric cancer: a 2014 update. World J Gastroenterol. 2014 Oct 14; 20(38):13637-47.
    View in: PubMed
    Score: 0.123
  33. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014 Oct 20; 32(30):3400-5.
    View in: PubMed
    Score: 0.123
  34. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44.
    View in: PubMed
    Score: 0.122
  35. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014; 86(5-6):336-9.
    View in: PubMed
    Score: 0.120
  36. Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther. 2014 Apr; 14(4):367-79.
    View in: PubMed
    Score: 0.118
  37. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013 Dec 01; 31(34):4306-10.
    View in: PubMed
    Score: 0.115
  38. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7.
    View in: PubMed
    Score: 0.115
  39. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013 Nov; 24(11):2854-9.
    View in: PubMed
    Score: 0.114
  40. Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. Oncology. 2013; 85(2):95-9.
    View in: PubMed
    Score: 0.113
  41. Ramucirumab: a novel antiangiogenic agent. Future Oncol. 2013 Jun; 9(6):789-95.
    View in: PubMed
    Score: 0.112
  42. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013 Apr; 15(2):146-51.
    View in: PubMed
    Score: 0.111
  43. Modern oncological approaches to gastric adenocarcinoma. Gastroenterol Clin North Am. 2013 Jun; 42(2):359-69.
    View in: PubMed
    Score: 0.110
  44. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6.
    View in: PubMed
    Score: 0.109
  45. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4.
    View in: PubMed
    Score: 0.107
  46. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404.
    View in: PubMed
    Score: 0.106
  47. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-2642.
    View in: PubMed
    Score: 0.106
  48. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology. 2012; 82(6):347-51.
    View in: PubMed
    Score: 0.105
  49. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. Onkologie. 2012; 35(4):204-9.
    View in: PubMed
    Score: 0.103
  50. Gastric cancer: apples will always be apples. J Clin Oncol. 2012 Mar 20; 30(9):1017-8; author reply 1019-20.
    View in: PubMed
    Score: 0.103
  51. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13.
    View in: PubMed
    Score: 0.103
  52. Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 01; 29(19):2732; author reply 2732-3.
    View in: PubMed
    Score: 0.098
  53. ASO Visual Abstract: Survival Outcomes for Patients Who Have Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy. Ann Surg Oncol. 2024 Dec; 31(13):9063-9064.
    View in: PubMed
    Score: 0.062
  54. Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy. Ann Surg Oncol. 2024 Oct; 31(10):6918-6930.
    View in: PubMed
    Score: 0.061
  55. Updated Analysis of a Phase 2 Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Peritoneal Carcinoma from Gastric Cancer. Ann Surg Oncol. 2024 May; 31(5):2824-2825.
    View in: PubMed
    Score: 0.059
  56. Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma. Cancers (Basel). 2023 Oct 25; 15(21).
    View in: PubMed
    Score: 0.058
  57. Clinical Impact of Positive Surgical Margins in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2023 Aug; 30(8):4936-4945.
    View in: PubMed
    Score: 0.056
  58. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol. 2021 Mar; 123(4):911-922.
    View in: PubMed
    Score: 0.048
  59. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021 01; 27(1):141-151.
    View in: PubMed
    Score: 0.047
  60. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. J Gastrointest Surg. 2021 06; 25(6):1380-1387.
    View in: PubMed
    Score: 0.046
  61. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol. 2020 Sep; 122(3):422-432.
    View in: PubMed
    Score: 0.046
  62. Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology. 2020; 98(8):542-548.
    View in: PubMed
    Score: 0.045
  63. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018 07; 98:23-29.
    View in: PubMed
    Score: 0.040
  64. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.